Bladder, kidney, and other urologic cancers

Drug Name

• Adverse Events Associated With Outcomes in PD-1/PD-L1–Treated Urothelial Carcinoma
• AFINITOR
• AVASTIN
• BALVERSA
• BAVENCIO
• Benefit Seen from Frontline Pembrolizumab Plus Axitinib in Patients With Intermediate- or Poor-Risk Advanced RCC
• Bladder Cancer Linked to Early Menopause in Smokers
• Bladder Cancer Surgery Delay Increases Death Risk
• Bladder Cancer Surgery Outcomes Better Among Statin Users
• CABOMETYX
• Checkpoint Inhibitor-Based Combination Prolonged Progression in RCC
• Cisplatin
• Combination of ICIs and Cytoreductive Surgery in Metastatic RCC Appears Promising
• COSMEGEN
• Cytoreductive Nephrectomy Alone for mRCC Linked to Better Survival
• DEPO-PROVERA
• Doxorubicin HCl
• Doxorubicin HCl Solution
• Enfortumab Vedotin Yields High Response Rate in Advanced Urothelial Cancer
• First Targeted Therapy for Metastatic Bladder Cancer Gets FDA Approval
• Frailty Predicts Higher In-Hospital Mortality After Radical Cystectomy
• IMFINZI
• INLYTA
• KEYTRUDA
• LENVIMA
• MVASI
• NEXAVAR
• Nivolumab Plus Ipilimumab Proven Cost Effective in Advanced RCC
• OPDIVO
• Percutaneous Ablation Appropriate for Localized Renal Tumors
• Poor Diabetes Control Linked to Worse NMIBC Outcomes
• PROLEUKIN
• Prostatic Urethral Involvement Tied to Worse Outcomes in NMIBC
• Rise in TSH: A Prognostic Indicator in Sunitinib-Treated Metastatic RCC?
• SUTENT
• TECENTRIQ
• TEPADINA
• Thiotepa
• TICE BCG
• TORISEL
• VALSTAR
• Vincristine Sulfate PFS
• VOTRIENT
• YERVOY